Has Aubrey de Grey publicly confirmed taking any specific longevity drugs?

De Grey has confirmed taking basic supplements (vitamin D, omega-3s) in podcast appearances and conference Q&As. He has not publicly confirmed taking prescription longevity compounds such as rapamycin, metformin, or senolytic combinations. His public statements emphasize caution and waiting for better clinical evidence.

What is the SENS framework for aging?

SENS (Strategies for Engineered Negligible Senescence) identifies seven categories of molecular and cellular damage that accumulate with age. The framework argues that repairing or removing this damage, rather than slowing its accumulation, is the most promising path to extending healthy lifespan. Categories include senescent cell accumulation, mitochondrial mutations, and extracellular protein crosslinks.

Are senolytics safe to take without a doctor?

No. The most studied senolytic combination (dasatinib + quercetin) includes dasatinib, a chemotherapy drug with significant potential side effects including myelosuppression and cardiac toxicity. Even intermittent "hit and run" protocols require medical supervision and lab monitoring. Quercetin alone is generally safe as a supplement but unlikely to produce senolytic effects without dasatinib.

What is the difference between NMN and NR?

Both are precursors to NAD+. NMN (nicotinamide mononucleotide) is one step closer to NAD+ in the biosynthetic pathway. NR (nicotinamide riboside) must first be converted to NMN, then to NAD+. Both raise blood NAD+ levels in humans, though head-to-head comparison trials are limited. Neither has proven longevity benefits in human clinical trials as of 2026.

Does the HealthRX Medical Team recommend rapamycin for longevity?

The HealthRX Medical Team classifies low-dose intermittent rapamycin as a Tier 2 compound: promising preclinical data exists, but long-term human safety and efficacy for longevity remain unproven. Any use should occur under physician supervision with regular metabolic and immune function monitoring. Self-prescribing rapamycin carries real immunosuppressive risk.

Aubrey de Grey and Longevity: The Documented Public Record

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Who: Aubrey de Grey, Ph.D., biomedical gerontologist and co-founder of the SENS Research Foundation
Drug family: Longevity (senolytics, NAD+ precursors, mTOR inhibitors, and related research compounds)
Status: Confirmed personal interest and partial self-experimentation; full regimen details not publicly disclosed
Public timeline: Active public commentary from approximately 2003 to present
Key compounds discussed publicly: Senolytic agents (dasatinib + quercetin), NAD+ pathway molecules (NMN, NR), rapamycin/rapalogs, metformin

Who Is Aubrey de Grey?

Aubrey de Grey holds a Ph.D. in biology from the University of Cambridge and spent over two decades arguing that biological aging is an engineering problem with identifiable, fixable damage categories. He co-founded the SENS Research Foundation in 2009 and co-authored Ending Aging (2007), a book that laid out seven categories of cellular and molecular damage he proposed as the root causes of age-related decline.

His public profile is unusual among longevity figures. De Grey is not a clinician prescribing protocols. He is a theorist and fundraiser whose influence comes from framing aging as a medical condition rather than an inevitability. That framing has shaped how an entire generation of researchers, biohackers, and patients think about interventional gerontology.

What Aubrey de Grey Has Publicly Confirmed

In multiple podcast appearances (including episodes of the Lex Fridman Podcast and Joe Rogan Experience), de Grey has confirmed that he personally takes a modest supplement stack oriented toward longevity. He has described this as conservative relative to what some biohackers adopt, stating in interviews that he prefers to wait for stronger clinical evidence before adding compounds.

Confirmed public statements include:

General supplement use. De Grey has acknowledged taking basic supplements (vitamin D, omega-3 fatty acids) and has referenced these in public Q&A sessions at longevity conferences.
Academic engagement with senolytics. Through SENS, de Grey has funded and promoted research into senolytic compounds, agents that selectively clear senescent cells. He has discussed the dasatinib + quercetin combination in academic contexts repeatedly, calling it one of the more promising near-term interventions.
Interest in NAD+ biology. De Grey has publicly discussed nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) as areas of active research. In conference presentations, he has referenced the preclinical work on NAD+ decline with age, though he has been measured in endorsing supplementation before large human trials report.
Skepticism of single-compound solutions. A consistent theme in de Grey's public commentary is that no single molecule will meaningfully extend human lifespan. He has stated this position in his 2023 appearance on the Tim Ferriss Show podcast, arguing that combination therapies targeting multiple damage categories simultaneously are the only plausible path to significant life extension.

What Remains Speculated

Several claims circulate in biohacking forums and longevity communities that lack direct confirmation from de Grey himself:

Rapamycin or rapalog use. Some online communities have attributed rapamycin use to de Grey based on his positive public comments about mTOR inhibition research. De Grey has discussed the ITP (Interventions Testing Program) rapamycin data extensively but has not publicly confirmed personal use.
Metformin use. Similarly, de Grey has referenced the TAME (Targeting Aging with Metformin) trial in interviews as an important clinical milestone. Whether he takes metformin personally is not publicly confirmed.
Senolytic self-experimentation. While de Grey has championed senolytic research through SENS, there is no confirmed public statement that he personally undergoes periodic senolytic dosing (the "hit and run" protocol some longevity physicians use). This remains speculated.

The distinction matters. De Grey's public role is as a research strategist, not a self-experimenter in the mold of Bryan Johnson. Attributing specific drug use without confirmation misrepresents his publicly stated approach.

Clinical Context: The Compounds de Grey Discusses

Senolytics (Dasatinib + Quercetin)

Senescent cells accumulate with age, secreting pro-inflammatory factors collectively called the senescence-associated secretory phenotype (SASP). The landmark 2015 paper by Zhu et al. in Aging Cell demonstrated that a combination of dasatinib (a tyrosine kinase inhibitor approved for leukemia) and quercetin (a plant flavonoid) could selectively eliminate senescent cells in mice, improving physical function and extending healthspan.

Human data is still early. A small pilot study in patients with idiopathic pulmonary fibrosis showed the combination reduced senescent cell markers after intermittent dosing. Larger trials are underway. The side effect profile of dasatinib includes myelosuppression, fluid retention, and QT prolongation, making unsupervised use a genuine clinical risk. Quercetin alone is well-tolerated at typical supplement doses but has low oral bioavailability.

NAD+ Precursors (NMN and NR)

Nicotinamide adenine dinucleotide (NAD+) levels decline with age, and this decline is associated with mitochondrial dysfunction, DNA repair impairment, and metabolic deterioration. NMN and NR are precursors that can raise NAD+ levels in humans, as confirmed by pharmacokinetic studies published in Nature Communications.

Whether raising NAD+ levels translates to clinically meaningful lifespan or healthspan extension in humans is unresolved. The 2024 systematic review in GeroScience found improvements in some biomarkers but no definitive evidence of functional outcomes in healthy adults. Common side effects are mild: flushing, GI discomfort, and occasional insomnia at higher doses.

The HealthRX Medical Team Longevity Compound Risk Framework

The HealthRX Medical Team categorizes longevity compounds into three tiers based on current evidence quality and risk profile:

Tier 1 (Strong human safety data, modest longevity signal): Metformin, vitamin D, omega-3 fatty acids, exercise mimetics in early trials. These carry well-characterized side effect profiles from decades of clinical use for other indications.

Tier 2 (Promising preclinical/early clinical data, moderate risk): NAD+ precursors (NMN, NR), rapamycin at low intermittent doses, spermidine. Human safety data exists but long-term longevity outcomes remain unproven. Rapamycin carries immunosuppressive risks even at low doses, as documented in FDA prescribing information.

Tier 3 (Early-stage, higher risk without supervision): Senolytic combinations (dasatinib + quercetin), experimental peptides (epithalon, FOXO4-DRI), gene therapy approaches. These should only be considered under direct physician oversight with appropriate lab monitoring.

De Grey's public statements generally align with caution about Tier 3 compounds for individual use while arguing aggressively for more research funding to move them through clinical development.

Rapamycin and mTOR Inhibition

Rapamycin (sirolimus) extended lifespan in mice by 9-14% in the NIA Interventions Testing Program, one of the most strong results in the longevity field. The drug inhibits mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway linked to growth, autophagy, and cellular senescence.

In humans, rapamycin is FDA-approved for organ transplant rejection and certain cancers. Off-label longevity use typically involves low, intermittent dosing (often 3-6 mg weekly) to capture autophagy-promoting effects while minimizing immunosuppression. A 2014 study by Mannick et al. in Science Translational Medicine showed that the rapalog everolimus improved immune function in older adults at low doses, providing early human evidence for the approach.

Side effects at immunosuppressive doses include mouth ulcers, hyperlipidemia, impaired wound healing, and increased infection risk. Whether intermittent low-dose protocols meaningfully reduce these risks over years of use remains an open question.

Metformin

Metformin, a first-line type 2 diabetes drug, emerged as a longevity candidate after observational studies suggested diabetic patients on metformin lived longer than non-diabetic controls. The proposed mechanisms include AMPK activation, reduced mTOR signaling, and anti-inflammatory effects.

The TAME trial, which de Grey has referenced publicly, aims to test metformin's ability to delay a composite of age-related diseases in non-diabetic older adults. The trial's enrollment and design have been discussed in The Journals of Gerontology. Common side effects include GI disturbance (nausea, diarrhea), vitamin B12 depletion with long-term use, and rare lactic acidosis in patients with renal impairment.

The HealthRX Medical Team Take

Aubrey de Grey occupies a specific niche in longevity discourse: the theorist who builds frameworks rather than personal protocols. His SENS model, which categorizes aging damage into seven repairable types (mitochondrial mutations, intracellular junk, extracellular junk, cell loss, cell senescence, extracellular crosslinks, and nuclear mutations), remains influential even as the field has evolved beyond some of its original assumptions.

From a clinical perspective, the HealthRX Medical Team notes three important distinctions about de Grey's public record:

First, his confirmed supplement use is conservative. This contrasts with the perception some audiences have of longevity researchers as aggressive self-experimenters. His stated approach, waiting for stronger evidence before adopting compounds, is actually closer to standard medical practice than many biohacker protocols.

Second, his advocacy for combination therapies targeting multiple aging pathways simultaneously has clinical merit. Single-target interventions have historically underperformed in complex diseases, and aging is arguably the most complex biological process. The Geroscience Hypothesis, published in Cell, supports the view that targeting fundamental aging mechanisms could delay multiple diseases simultaneously.

Third, the gap between de Grey's public research advocacy and what individuals can safely do today is significant. Many of the compounds he champions (senolytic combinations, gene therapies, mitochondrial allotopic expression) are years from validated clinical protocols. Patients inspired by his framework should work with physicians trained in longevity medicine rather than self-prescribing research compounds.

The bottom line: de Grey's contribution is conceptual, not pharmacological. His public record shows a researcher who has shaped how we think about aging interventions while maintaining a relatively cautious personal approach to the compounds he promotes for research.

Frequently asked questions

›

References

Zhu Y, et al. "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs." Aging Cell. 2015. https://pubmed.ncbi.nlm.nih.gov/25754370/
Justice JN, et al. "Senolytics in idiopathic pulmonary fibrosis." EBioMedicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30616998/
Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021. https://pubmed.ncbi.nlm.nih.gov/36609564/
Harrison DE, et al. "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice." Nature. 2009. https://pubmed.ncbi.nlm.nih.gov/19587680/
Mannick JB, et al. "mTOR inhibition improves immune function in the elderly." Science Translational Medicine. 2014. https://pubmed.ncbi.nlm.nih.gov/25540326/
Bannister CA, et al. "Can people with type 2 diabetes live longer than those without?" Diabetes, Obesity and Metabolism. 2014. https://pubmed.ncbi.nlm.nih.gov/25041462/
Barzilai N, et al. "Metformin as a Tool to Target Aging." Cell Metabolism. 2016. https://pubmed.ncbi.nlm.nih.gov/31802682/
Kennedy BK, et al. "Geroscience: linking aging to chronic disease." Cell. 2014. https://pubmed.ncbi.nlm.nih.gov/24786736/
FDA. "Rapamune (sirolimus) prescribing information." https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s064lbl.pdf